Literature DB >> 19109563

A role for MEIS1 in MLL-fusion gene leukemia.

Ashish R Kumar1, Quanzhi Li, Wendy A Hudson, Weili Chen, Thien Sam, Qing Yao, Erik A Lund, Baolin Wu, Branden J Kowal, John H Kersey.   

Abstract

Leukemias with MLL rearrangements are characterized by high expression of the homeobox gene MEIS1. In these studies, we knocked down Meis1 expression by shRNA lentivirus transduction in murine Mll-AF9 leukemia cells. Meis1 knockdown resulted in decreased proliferation and survival of murine Mll-AF9 leukemia cells. We also observed reduced clonogenic capacity and increased monocytic differentiation. The establishment of leukemia in transplantation recipients was significantly delayed by Meis1 knockdown. Gene expression profiling of cells transduced with Meis1 shRNA showed reduced expression of genes associated with cell cycle entry and progression. shRNA-mediated knockdown of MEIS1 in human MLL-fusion gene leukemia cell lines resulted in reduced cell growth. These results show that MEIS1 expression is important for MLL-rearranged leukemias and suggest that MEIS1 promotes cell-cycle entry. Targeting MEIS1 may have therapeutic potential for treating leukemias expressing this transcription factor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19109563      PMCID: PMC2647665          DOI: 10.1182/blood-2008-06-163287

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

Review 1.  A new look at Rho GTPases in cell cycle: role in kinetochore-microtubule attachment.

Authors:  Shuh Narumiya; Fabian Oceguera-Yanez; Shingo Yasuda
Journal:  Cell Cycle       Date:  2004-07-25       Impact factor: 4.534

2.  Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL.

Authors:  C Lavau; S J Szilvassy; R Slany; M L Cleary
Journal:  EMBO J       Date:  1997-07-16       Impact factor: 11.598

3.  The mll-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis.

Authors:  C L Dobson; A J Warren; R Pannell; A Forster; I Lavenir; J Corral; A J Smith; T H Rabbitts
Journal:  EMBO J       Date:  1999-07-01       Impact factor: 11.598

Review 4.  Cyclins and cdks in development and cancer: a perspective.

Authors:  Amit Deshpande; Peter Sicinski; Philip W Hinds
Journal:  Oncogene       Date:  2005-04-18       Impact factor: 9.867

Review 5.  Cyclin A2 transcriptional regulation: modulation of cell cycle control at the G1/S transition by peripheral cues.

Authors:  J M Blanchard
Journal:  Biochem Pharmacol       Date:  2000-10-15       Impact factor: 5.858

6.  Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells.

Authors:  Weili Chen; Ashish R Kumar; Wendy A Hudson; Quanzhi Li; Baolin Wu; Rodney A Staggs; Erik A Lund; Thien N Sam; John H Kersey
Journal:  Cancer Cell       Date:  2008-05       Impact factor: 31.743

7.  In vitro culture of leukemic cells in t(4;11) acute leukemia.

Authors:  R C Stong; J H Kersey
Journal:  Blood       Date:  1985-08       Impact factor: 22.113

8.  Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential.

Authors:  Piu Wong; Masayuki Iwasaki; Tim C P Somervaille; Chi Wai Eric So; Chai Wai Eric So; Michael L Cleary
Journal:  Genes Dev       Date:  2007-10-17       Impact factor: 11.361

9.  Hoxa9 influences the phenotype but not the incidence of Mll-AF9 fusion gene leukemia.

Authors:  Ashish R Kumar; Wendy A Hudson; Weili Chen; Ritsuo Nishiuchi; Qing Yao; John H Kersey
Journal:  Blood       Date:  2003-11-13       Impact factor: 22.113

10.  NCBI GEO: mining tens of millions of expression profiles--database and tools update.

Authors:  Tanya Barrett; Dennis B Troup; Stephen E Wilhite; Pierre Ledoux; Dmitry Rudnev; Carlos Evangelista; Irene F Kim; Alexandra Soboleva; Maxim Tomashevsky; Ron Edgar
Journal:  Nucleic Acids Res       Date:  2006-11-11       Impact factor: 16.971

View more
  53 in total

1.  Promoter variants in the MSMB gene associated with prostate cancer regulate MSMB/NCOA4 fusion transcripts.

Authors:  Hong Lou; Hongchuan Li; Meredith Yeager; Kate Im; Bert Gold; Thomas D Schneider; Joseph F Fraumeni; Stephen J Chanock; Stephen K Anderson; Michael Dean
Journal:  Hum Genet       Date:  2012-06-04       Impact factor: 4.132

2.  Down-regulation of homeobox genes MEIS1 and HOXA in MLL-rearranged acute leukemia impairs engraftment and reduces proliferation.

Authors:  Kira Orlovsky; Alexander Kalinkovich; Tanya Rozovskaia; Elias Shezen; Tomer Itkin; Hansjuerg Alder; Hatice Gulcin Ozer; Letizia Carramusa; Abraham Avigdor; Stefano Volinia; Arthur Buchberg; Alex Mazo; Orit Kollet; Corey Largman; Carlo M Croce; Tatsuya Nakamura; Tsvee Lapidot; Eli Canaani
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

3.  Meis1 maintains stemness signature in MLL-AF9 leukemia.

Authors:  Ashish R Kumar; Aaron L Sarver; Baolin Wu; John H Kersey
Journal:  Blood       Date:  2010-04-29       Impact factor: 22.113

Review 4.  Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.

Authors:  Bin E Li; Patricia Ernst
Journal:  Exp Hematol       Date:  2014-09-28       Impact factor: 3.084

5.  Pbx1 restrains myeloid maturation while preserving lymphoid potential in hematopoietic progenitors.

Authors:  Francesca Ficara; Laura Crisafulli; Chenwei Lin; Masayuki Iwasaki; Kevin S Smith; Luca Zammataro; Michael L Cleary
Journal:  J Cell Sci       Date:  2013-05-09       Impact factor: 5.285

6.  TGIF1 is a negative regulator of MLL-rearranged acute myeloid leukemia.

Authors:  A Willer; J S Jakobsen; E Ohlsson; N Rapin; J Waage; M Billing; L Bullinger; S Karlsson; B T Porse
Journal:  Leukemia       Date:  2014-10-28       Impact factor: 11.528

7.  PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway.

Authors:  J Zhou; J Wu; B Li; D Liu; J Yu; X Yan; S Zheng; J Wang; L Zhang; L Zhang; F He; Q Li; A Chen; Y Zhang; X Zhao; Y Guan; X Zhao; J Yan; J Ni; M A Nobrega; B Löwenberg; R Delwel; P J M Valk; A Kumar; L Xie; D G Tenen; G Huang; Q-F Wang
Journal:  Leukemia       Date:  2013-12-26       Impact factor: 11.528

8.  Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.

Authors:  Scott R Daigle; Edward J Olhava; Carly A Therkelsen; Christina R Majer; Christopher J Sneeringer; Jeffrey Song; L Danielle Johnston; Margaret Porter Scott; Jesse J Smith; Yonghong Xiao; Lei Jin; Kevin W Kuntz; Richard Chesworth; Mikel P Moyer; Kathrin M Bernt; Jen-Chieh Tseng; Andrew L Kung; Scott A Armstrong; Robert A Copeland; Victoria M Richon; Roy M Pollock
Journal:  Cancer Cell       Date:  2011-07-12       Impact factor: 31.743

9.  MEIS1-mediated transactivation of synaptotagmin-like 1 promotes CXCL12/CXCR4 signaling and leukemogenesis.

Authors:  Takashi Yokoyama; Mayuka Nakatake; Takeshi Kuwata; Arnaud Couzinet; Ryo Goitsuka; Shuichi Tsutsumi; Hiroyuki Aburatani; Peter J M Valk; Ruud Delwel; Takuro Nakamura
Journal:  J Clin Invest       Date:  2016-03-28       Impact factor: 14.808

10.  PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease.

Authors:  Zejuan Li; Ping Chen; Rui Su; Chao Hu; Yuanyuan Li; Abdel G Elkahloun; Zhixiang Zuo; Sandeep Gurbuxani; Stephen Arnovitz; Hengyou Weng; Yungui Wang; Shenglai Li; Hao Huang; Mary Beth Neilly; Gang Greg Wang; Xi Jiang; Paul P Liu; Jie Jin; Jianjun Chen
Journal:  Cancer Res       Date:  2016-01-08       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.